MICHELE KEESLING: Open Payments
NPI 1659824332 · GALAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,431 in 78 payments from 15 companies in 2025. Trend: 2023 $854 · 2024 $1,360 · 2025 $1,431
Food & beverage: $1,430Education: $1
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $408 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $240 |
| Vanda Pharmaceuticals Inc. | 9 | $169 |
| Otsuka America Pharmaceutical, Inc. | 6 | $119 |
| AstraZeneca Pharmaceuticals LP | 6 | $102 |
| Novo Nordisk Inc | 5 | $89 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Lilly USA, LLC | 3 | $59 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Alkermes, Inc. | 2 | $36 |
Products named: VRAYLAR, CAPLYTA, REXULTI, AIRSUPRA, UBRELVY, FANAPT, HETLIOZ, Auvelity.
Industry payments across VA — which companies pay providers there.
